Treatment with GLP1 receptor agonists reduce serum CRP concentrations in patients with type 2 diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials

Mazidi, Mohsen, Karimi, Ehsan, Rezaie, Peyman and Ferns, Gordon A (2016) Treatment with GLP1 receptor agonists reduce serum CRP concentrations in patients with type 2 diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials. Journal of Diabetes and its Complications. ISSN 1056-8727

[img] PDF - Accepted Version
Available under License Creative Commons Attribution-NonCommercial No Derivatives.

Download (1MB)

Abstract

Aim: To undertake a systematic review and meta-analysis of randomized controlled trials of the effect of Glucagon-like peptide-1 receptor agonist (GLP-1 RAs) therapy on serum C-reactive protein (CRP) concentrations.

Method: PubMed-Medline, SCOPUS, Web of Science and Google Scholar databases were searched for the period up until March 16 2016. Prospective studies evaluating the impact of GLP-1 RAs on serum CRP were identified. A random effects model (using the DerSimonian-Laird method) and generic inverse variance methods were used for quantitative data synthesis. Sensitivity analysis was conducted using the leave-one-out method. Heterogeneity was quantitatively assessed using the I2 index. Random effects meta-regression was performed using unrestricted maximum likelihood method to evaluate the impact of potential moderator.

International Prospective Register for Systematic Reviews (PROSPERO) number CRD42016036868.

Results: Meta-analysis of the data from 7 treatment arms revealed a significant reduction in serum CRP concentrations following treatment with GLP-1 RAs (WMD –2.14 (mg/dL), 95% CI -3.51, –0.78, P=0.002; I2 96.1%). Removal of one study in the meta-analysis did not change the result in the sensitivity analysis (WMD –2.14(mg/dL), 95% CI -3.51, –0.78, P=0.002; I2 96.1%), indicating that our results could not be solely attributed to the effect of a single study. Random effects meta-regression was performed to evaluate the impact of potential moderator on the estimated effect size. Changes in serum CRP concentration were associated with the duration of treatment (slope –0.097, 95% CI –0.158, -0.042, P<0.001).

Conclusions: This meta-analysis suggests that GLP-1 RAs therapy causes a significant reduction in CRP.

Item Type: Article
Keywords: meta-analysis Glucagon-like peptide-1 receptor agonist C-reactive protein
Schools and Departments: Brighton and Sussex Medical School > Division of Medical Education
Subjects: R Medicine
Depositing User: Elizabeth Morris
Date Deposited: 02 Jun 2016 09:19
Last Modified: 02 Jun 2017 07:29
URI: http://sro.sussex.ac.uk/id/eprint/61270

View download statistics for this item

📧 Request an update